Healthcare provider profile · identity verified

Daulton E Todd, MD

Allopathic & Osteopathic Physicians|Internal Medicine · CUMMING, GA · NPI 1447285770

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Daulton E Todd, MD received $18.82 in general payments during 2025 across 1 reported records.

Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$18.82

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$18.82	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$18.82	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$18.82	1	2025
Source payment records 2025-03-04 · Lilly USA, LLC · $18.82 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
MOUNJARO mounjaro	2025	Mounjaro	2024	14 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	79	13
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	721	136
Levothyroxine Sodium	Levothyroxine Sodium	703	110
Amlodipine Besylate	Amlodipine Besylate	698	90
Famotidine	Famotidine	540	66
Gabapentin	Gabapentin	455	89
Metoprolol Succinate	Metoprolol Succinate	439	75
Sertraline Hcl	Sertraline Hcl	439	35
Eliquis	Apixaban	436	66
Lisinopril	Lisinopril	390	52
Potassium Chloride	Potassium Chloride	386	40
Omeprazole	Omeprazole	385	82
Furosemide	Furosemide	358	47
Metoprolol Tartrate	Metoprolol Tartrate	349	45
Donepezil Hcl	Donepezil Hcl	338	26
Tamsulosin Hcl	Tamsulosin Hcl	298	60
Torsemide	Torsemide	278	37
Carvedilol	Carvedilol	268	36
Trazodone Hcl	Trazodone Hcl	268	38
Losartan Potassium	Losartan Potassium	266	58
Montelukast Sodium	Montelukast Sodium	253	23
Duloxetine Hcl	Duloxetine Hcl	249	36
Pravastatin Sodium	Pravastatin Sodium	249	44
Divalproex Sodium	Divalproex Sodium	224	12
Pantoprazole Sodium	Pantoprazole Sodium	223	62
Metformin Hcl	Metformin Hcl	200	45
Quetiapine Fumarate	Quetiapine Fumarate	200	23
Clopidogrel	Clopidogrel Bisulfate	186	31
Memantine Hcl	Memantine Hcl	186	16
Hydralazine Hcl	Hydralazine Hcl	179	36
Escitalopram Oxalate	Escitalopram Oxalate	176	25
Allopurinol	Allopurinol	175	28
Mirtazapine	Mirtazapine	165	28
Levetiracetam	Levetiracetam	155	14
Valsartan	Valsartan	146	13
Prednisone	Prednisone	143	27
Fenofibrate	Fenofibrate Nanocrystallized	138	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	125	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	124	37
Isosorbide Mononitrate Er	Isosorbide Mononitrate	112	12
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	100	99
Buspirone Hcl	Buspirone Hcl	98	16
Carbidopa-Levodopa	Carbidopa/Levodopa	98	16
Metformin Hcl Er	Metformin Hcl	96	23
Alprazolam	Alprazolam	95	19
Citalopram Hbr	Citalopram Hydrobromide	93	18
Meloxicam	Meloxicam	92	20
Hydrochlorothiazide	Hydrochlorothiazide	88	16
Finasteride	Finasteride	84	17
Fluoxetine Hcl	Fluoxetine Hcl	83	13
Celecoxib	Celecoxib	79	suppressed
Jardiance	Empagliflozin	79	13
Aripiprazole	Aripiprazole	77	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	74	54
Novolog Flexpen	Insulin Aspart	70	11
Metolazone	Metolazone	67	suppressed
Spironolactone	Spironolactone	67	21
Glimepiride	Glimepiride	66	20
Midodrine Hcl	Midodrine Hcl	66	21
Bupropion Xl	Bupropion Hcl	65	12
Propranolol Hcl	Propranolol Hcl	62	11
Albuterol Sulfate	Albuterol Sulfate	59	20
Atenolol	Atenolol	56	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	56	20
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	53	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	53	17
Tramadol Hcl	Tramadol Hcl	53	35
Ezetimibe	Ezetimibe	52	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	50	25
Methenamine Hippurate	Methenamine Hippurate	50	suppressed
Fluticasone Propionate	Fluticasone Propionate	49	32
Venlafaxine Hcl Er	Venlafaxine Hcl	49	suppressed
Baclofen	Baclofen	47	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	47	suppressed
Hydrocortisone	Hydrocortisone	46	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	45	suppressed
Amiodarone Hcl	Amiodarone Hcl	44	14
Esomeprazole Magnesium	Esomeprazole Magnesium	43	suppressed
Digoxin	Digoxin	42	suppressed
Lorazepam	Lorazepam	41	15
Simvastatin	Simvastatin	41	12
Zolpidem Tartrate	Zolpidem Tartrate	41	14
Entresto	Sacubitril/Valsartan	40	suppressed
Clonidine Hcl	Clonidine Hcl	39	suppressed
Januvia	Sitagliptin Phosphate	39	suppressed
Ropinirole Hcl	Ropinirole Hcl	39	suppressed
Terazosin Hcl	Terazosin Hcl	39	suppressed
Cilostazol	Cilostazol	38	suppressed
Cholestyramine	Cholestyramine (With Sugar)	37	15
Glipizide	Glipizide	36	suppressed
Temazepam	Temazepam	36	14
Cefdinir	Cefdinir	35	27
Insulin Aspart Flexpen	Insulin Aspart	35	22
Ondansetron Odt	Ondansetron	35	31
Nadolol	Nadolol	34	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	24
Doxycycline Hyclate	Doxycycline Hyclate	32	23
Dropsafe Pen Needle	Pen Needle, Diabetic, Safety	32	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	32	suppressed
Latanoprost	Latanoprost	31	17
Ondansetron Hcl	Ondansetron Hcl	31	27
Calcitriol	Calcitriol	30	suppressed
Myrbetriq	Mirabegron	30	suppressed
Bumetanide	Bumetanide	29	suppressed
Gemtesa	Vibegron	29	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	29	suppressed
Eplerenone	Eplerenone	27	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Pregabalin	Pregabalin	27	16
Unifine Safecontrol Pen Needle	Pen Needle,dual Safety,diabetc	27	23
Tradjenta	Linagliptin	26	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	25	suppressed
Diclofenac Sodium	Diclofenac Sodium	25	suppressed
Farxiga	Dapagliflozin Propanediol	25	suppressed
Methocarbamol	Methocarbamol	25	18
Nifedipine Er	Nifedipine	25	suppressed
Benazepril Hcl	Benazepril Hcl	23	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	23	22
Dexamethasone	Dexamethasone	23	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Meclizine Hcl	Meclizine Hcl	23	11
Cartia Xt	Diltiazem Hcl	21	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	21	11
Carbamazepine	Carbamazepine	20	suppressed
Alendronate Sodium	Alendronate Sodium	19	suppressed
Budesonide	Budesonide	19	suppressed
Creon	Lipase/Protease/Amylase	19	suppressed
Dapagliflozin	Dapagliflozin Propanediol	19	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	19	suppressed
Oxycodone Hcl	Oxycodone Hcl	19	16
Pioglitazone Hcl	Pioglitazone Hcl	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Misoprostol	Misoprostol	18	suppressed
Vascepa	Icosapent Ethyl	18	suppressed
Azithromycin	Azithromycin	17	16
Risperidone	Risperidone	17	suppressed
Cephalexin	Cephalexin	16	suppressed
Diflunisal	Diflunisal	16	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Nitroglycerin Patch	Nitroglycerin	15	suppressed
Trimethoprim	Trimethoprim	15	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	14	14
Fludrocortisone Acetate	Fludrocortisone Acetate	14	suppressed
Mounjaro	Tirzepatide	14	suppressed
Nitroglycerin	Nitroglycerin	14	12
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	11
Benztropine Mesylate	Benztropine Mesylate	13	suppressed
Ciclopirox	Ciclopirox Olamine	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Primidone	Primidone	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Premarin	Estrogens, Conjugated	12	suppressed
Cyclosporine	Cyclosporine	11	suppressed
Fluconazole	Fluconazole	11	11
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Nateglinide	Nateglinide	11	suppressed
Olanzapine	Olanzapine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$18.82 · 1 records	Lilly USA, LLC	MOUNJARO	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Mounjaro play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error